The present disclosure relates to a pharmaceutical kit for alleviating adverse effects of chemotherapy, reducing oxidative stress, improving immunomodulatory response and quality of life. The pharmaceutical kit comprises Suvarna bhasmadi Vati (SBD), Mouktikyukta Kamdudha Vati (MKD), Padmakadi Ghrut (PDG), and Ananta vati. The pharmaceutical kit of the present disclosure can be used for alleviating adverse effects of chemotherapy such as nausea, vomiting, anorexia, fever, taste alteration, fatigue, dyspepsia, and mucositis. It can also improve immune status and reduce oxidative stress leading to betterment of the quality of life of the patients treated with chemotherapy. The pharmaceutical kit of the present disclosure may be beneficial in cancers and diseases for which chemotherapy is a treatment of choice.

The present disclosure relates to a pharmaceutical kit for alleviating adverse effects of chemotherapy, reducing oxidative stress, improving immunomodulatory response and quality of life. The pharmaceutical kit comprises Suvarna bhasmadi Vati (SBD), Mouktikyukta Kamdudha Vati (MKD), Padmakadi Ghrut (PDG), and Ananta vati. The pharmaceutical kit of the present disclosure can be used for alleviating adverse effects of chemotherapy such as nausea, vomiting, anorexia, fever, taste alteration, fatigue, dyspepsia, and mucositis. It can also improve immune status and reduce oxidative stress leading to betterment of the quality of life of the patients treated with chemotherapy. The pharmaceutical kit of the present disclosure may be beneficial in cancers and diseases for which chemotherapy is a treatment of choice.

The present disclosure is a substance for providing health benefits that is comprised of at least one cannabinoid and pearl powder.

The present disclosure is a substance for providing health benefits that is comprised of at least one cannabinoid and pearl powder.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.

The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.

The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.

A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.

A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.